Mortality and costs of acute renal failure associated with amphotericin B therapy. - Wikidata - wikimedia - TriplyDB

Mortality and costs of acute renal failure associated with amphotericin B therapy.

Mortality and costs of acute renal failure associated with amphotericin B therapy.

http://www.wikidata.org/entity/Q32068576

about

Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function David Westfall Bates, MD: a conversation with the editor on improving patient safety, quality of care, and outcomes by using information technology. Interview by William Clifford Roberts Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia Awareness and knowledge among internal medicine house-staff for dose adjustment of commonly used medications in patients with CKD Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Enhanced propagation of adult human renal epithelial progenitor cells to improve cell sourcing for tissue-engineered therapeutic devices for renal diseases.Pharmacological advances in the treatment of invasive candidiasis.Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis Nanopharmaceuticals (part 1): products on the market.Masking of β(1-3)-glucan in the cell wall of Candida albicans from detection by innate immune cells depends on phosphatidylserine.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.The incidence and prognostic significance of acute kidney injury.Stem cells: the next therapeutic frontier.Acinetobacter baumannii: emergence of a successful pathogen The synthetic amphipathic peptidomimetic LTX109 is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner Acute kidney injury: controversies revisited.Caspofungin acetate for treatment of invasive fungal infections.Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis Therapeutic monitoring of amphotericin B in Saudi ICU patients using UPLC MS/MS assay.Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Amphotericin B lipid complex for the treatment of invasive fungal infections.Antifungal properties of peptidomimetics with an arginine-[β-(2,5,7-tri-tert-butylindol-3-yl)alanine]-arginine motif against Saccharomyces cerevisiae and Zygosaccharomyces bailii.Changing strategies for the management of invasive fungal infections.Clinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Macrophages mediate lung inflammation in a mouse model of ischemic acute kidney injury.Antifungal chemotherapeutics.Experience with community-based amphotericin B infusion therapy.Liposomal amphotericin B: clinical experience and perspectives.An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada.Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.Emerging echinocandins for treatment of invasive fungal infections.The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.The safety of anidulafungin.

P2860

Q24187699-8690FBD0-97F4-45B0-B9EF-DE30AC3CC053 Q24198155-170C78CF-A960-493E-83D6-9FF5B4C05EEC Q24531987-B8B9EADD-3DEF-4670-98D8-6F74E9DAF0B6 Q24563657-5F217F39-D225-4D8B-95D3-44CA37DF5D42 Q28468296-11203587-E33A-4140-8915-F1B637433975 Q30240770-92E2BC5E-FB49-4838-9FFE-2290554E10E5 Q30522328-08572015-2CAC-4BDD-8278-27CAD20949A8 Q33232599-8FB7BF8E-94CD-4820-AB54-66B4BFBD5E28 Q33409652-BE36D466-A6AF-4700-AC66-64BC3118311C Q33816237-BD4544C1-1DE8-4F17-BAF7-73462F32968D Q33876645-705F43D5-2876-470E-ADD7-BE8B049F29D4 Q34045435-AF123311-7E99-43A1-B804-07D1547CD80F Q34230175-DBE74F93-7CE4-4C5D-BF90-3A15BDE8F16F Q34298661-DCB2EDDE-BC43-4ADE-BC57-13A0125B3A27 Q34505582-5766BBAC-46A5-478C-8C10-F49AE40F8D2C Q34523413-BDD084C9-04F0-46BA-A12B-2F7F0476FF9B Q34655082-54EB09C2-2148-4E5C-ABBF-9627B18FBC4D Q34795807-9D10223B-39F2-4EB8-9706-EE3F439098E0 Q34854161-D3B02E5F-F05B-47E5-9C5D-EF80BD0D9661 Q35024877-49CF3FF8-09A0-4380-B120-C533286BA106 Q35035091-CC36A68D-5B7B-486C-906A-464691572804 Q35127833-DEC8641D-855F-448D-8039-D5CFC29CBE40 Q35148135-59D7DD4B-0E2C-462A-B644-5D86C48CA8B4 Q35557331-0921F117-EB54-4749-9F53-4FEFA44D01DC Q35575017-B46FDCBE-520B-4CCD-8D7A-4AC64BA7E354 Q35575367-D3CBF809-C896-455D-9923-BACE2DA02EAA Q35678997-B9670591-ADE7-4278-B3E4-60FB128BCC0B Q35738800-87E95EE9-A103-4152-9845-BBC67555151C Q35746695-14F983E7-02DB-45BF-BF17-45E7B0FDA3F2 Q35787428-79EB91B8-07E9-4273-9F03-E60A52154E0A Q36111677-8A9DE0C8-3D6A-49F3-88A7-D293FD660C52 Q36130619-E3B34691-FB09-4CA4-B548-E88B0FCFC157 Q36140647-6388AB0A-7752-4BAA-9D15-826F7B83A1FE Q36170887-CECBF700-4561-46AA-B06B-72FBA1547963 Q36326220-A6E9978A-27CB-40A7-A728-FE4189D4070C Q36383044-8D0DFFFA-4736-4F25-9D3E-2C3AED1B8BF0 Q36458402-31047D84-BE26-490B-91DE-B868E4A1627B Q36482888-477D3F89-8965-4A8D-AE67-E74C273EACAB Q36484942-52FC3AA5-E31E-42BD-AC9F-22F4082F0914 Q36624970-CCCDB057-6C55-4DB3-A940-A127DB7AADD0

P2860

Mortality and costs of acute renal failure associated with amphotericin B therapy.

http://www.wikidata.org/entity/Q32068576

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

name

Mortality and costs of acute renal failure associated with amphotericin B therapy.

@ast

Mortality and costs of acute renal failure associated with amphotericin B therapy.

@en

type

label

Mortality and costs of acute renal failure associated with amphotericin B therapy.

@ast

Mortality and costs of acute renal failure associated with amphotericin B therapy.

@en

prefLabel

Mortality and costs of acute renal failure associated with amphotericin B therapy.

@ast

Mortality and costs of acute renal failure associated with amphotericin B therapy.

@en

P1433

Q32068576-98BD693B-F498-4376-96EB-F14F1ACC2F19

P1476

Q32068576-63648CBA-A7D5-4FCB-BB8D-E9CB397A2A77

P2093

Q32068576-0FD70A23-65E1-4DB9-9094-A61FF4A0E2BF

Q32068576-357E59C2-A28C-4B0E-A2E1-A7B8355A8A3B

Q32068576-4045D75A-AE66-4254-8BA4-2E5C56C1BEA6

Q32068576-7F6F0CFF-A153-49B7-88AB-B77DB6E5146A

Q32068576-A18407C7-0BEF-4041-B698-A4D4A31D27AD

Q32068576-AE6CB1B7-2F46-4F0D-9DAA-54FF8E7C4D87

Q32068576-AEAF06EC-80E2-4B13-828F-ECE75B3C76AE

Q32068576-B6B766E6-CC8A-4D2C-9C99-2B073F0743BC

P2860

Q32068576-00B0B339-BA0F-446A-8F7A-BE45D3C4AFDD

Q32068576-0599A829-C283-4ACF-8F3E-9A7A17B4F6A8

Q32068576-10105EE2-15DF-49D9-B8C9-08057B8FA01A

Q32068576-180FB049-5AA9-4F4A-9849-FA40EA01A901

Q32068576-34EB3A58-971B-4037-8185-A64D8E1335D8

Q32068576-372736D6-16A7-4429-9B0B-090F6102BEAC

Q32068576-51E81467-6C1C-42F9-A93F-51F9912AFD06

Q32068576-5487A3CD-6FC3-46C6-9648-C195419D2F58

Q32068576-54AC2DA3-E8C4-46DA-B070-4FBE12425785

Q32068576-6DAAEE03-2D86-423A-9A74-3FA8AC126FE4

P304

Q32068576-645EC0DC-0E76-41E7-A760-E95C2B3D3845

P31

Q32068576-B8F416C6-6929-4A56-90A2-F86A66E91A09

P356

Q32068576-4DB15393-E79E-48C5-A1C8-CF1D8FA05DB3

P407

Q32068576-0AF79AE8-F47D-4B5B-BC01-936C5DE06631

P433

Q32068576-E1ACF44D-6B35-4F07-ABDA-C901FD873D83

P478

Q32068576-6302FDBE-474C-4B19-8BF5-CF6FB80A8F1A

P577

Q32068576-02ECF3AA-F520-48E0-97CF-4354685A57A7

P5875

Q32068576-2341032A-89EA-4323-B036-DC8F51493E64

P698

Q32068576-B6BF174D-3A79-4DFC-8452-89CBFEF36E81

P356

P1433

Clinical Infectious Diseases

P1476

Mortality and costs of acute renal failure associated with amphotericin B therapy.

@en

P2093

Bates DW

http://www.w3.org/2001/XMLSchema#string

Chertow GM

http://www.w3.org/2001/XMLSchema#string

Dasbach EJ

http://www.w3.org/2001/XMLSchema#string

Gomes DR

http://www.w3.org/2001/XMLSchema#string

Platt R

http://www.w3.org/2001/XMLSchema#string

Seger DL

http://www.w3.org/2001/XMLSchema#string

Su L

http://www.w3.org/2001/XMLSchema#string

Yu DT

http://www.w3.org/2001/XMLSchema#string

P2860

Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Renal tubular acidosis due to amphotericin B.

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.

Drug-induced nephrotoxicity. Aetiology, clinical features and management.

Effect of salt supplementation on amphotericin B nephrotoxicity.

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.

Drug nephrotoxicity.

Hospital-acquired fungemia. Its natural course and clinical significance.

P304

686-693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/319211

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2001-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12101580

http://www.w3.org/2001/XMLSchema#string

P698

11229835

http://www.w3.org/2001/XMLSchema#string